Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Running head: immune-inflammatory and O&NS pathways in depression

(1) George Anderson, (2-5) Michael Berk; (2,3,5) Olivia Dean; (2) Steven Moylan; (2,6) Michael Maes.

(1) CRC, Rm:30, 57 Laurel Street, Glasgow, Scotland

(2) IMPACT Strategic Research Centre and School of Medicine, Deakin University, Geelong, Australia

(3) The University of Melbourne, Department of Psychiatry, Parkville, Australia

(4) Orygen Youth Health Research Centre, Parkville, Australia

(5) Florey Institute for Neuroscience and Mental Health, Parkville, Australia

(6) Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand.

Corresponding author

George Anderson, CRC, Rm 30, 57 Laurel St. Glasgow G11 7QT, Scotland

Email: anderson.george@rocketmail.com

Phone: +447 505 623 759

Declaration of financial interests: None

Abstract

Accumulating data has led to a re-conceptualization of depression that emphasizes the role of immune-inflammatory processes, coupled to oxidative and nitrosative stress (O&NS). These in turn drive the production of neuroregulatory tryptophan catabolites (TRYCATs), driving tryptophan away from serotonin, melatonin and N-acetylserotonin production, and contributing to central dysregulation. This revised perspective better encompasses the diverse range of biological changes occurring in depression and in doing so provides novel and readily attainable treatment targets, as well as potential screening investigations prior to treatment initiation. Here we briefly review the role that immune-inflammatory, O&NS and TRYCAT pathways play in the etiology, course and treatment of depression. We then discuss the pharmacological treatment implications arising from this, including the potentiation of currently available antidepressants by the adjunctive use of immune-and O&NS-targeted therapies. The utilization of such a frame of reference and the treatment benefits attained are likely to have wider implications and utility for depression associated conditions, including the neuroinflammatory and (neuro)degenerative disorders.

1. Introduction

Historically, depression has been variously conceptualized, ranging from a psychoanalytical entity to a neuronal disorder dependent on monoamine dysregulation. The serotonin hypothesis of depression was mainly based on the findings that compounds with clinical antidepressant effects, e.g. iproniazid and imipramine, increase available serotonin [1]. Following the launch of selective serotonin reuptake inhibitors (SSRIs) the blaze of publicity undoubtedly enhanced the placebo effects that are relevant to all psychotropic medications [2]. Although the use of these agents has led to significant improvements in treatment outcomes, many patients continue to suffer depression-related morbidity, stressing the need for new treatments based on an evolving understanding of depression pathogenesis.

More recent conceptualizations of depression's biological underpinnings emphasize the role of oxidative and nitrosative stress (O&NS) coupled to immune-inflammatory pathways [3-5]. A large body of data shows that depression is associated with increased levels of immune-inflammatory processes as well as genetic and epigenetic changes in redox status [1,3]. The changes driven by immune-inflammatory and O&NS pathways incorporate many disparate aspects of depression, including: decreased serotonin, dopamine and norepinephrine (NE); circadian and melatonin dysregulation; transition to O&NS-induced damage and autoimmunity; decreased neurogenesis and neurodegenerative processes; reduction in brain volume with progression and changes over the course of depressive episodes; chronicity and treatment resistance [6]. Activated immune-inflammatory and O&NS pathways also explain the high association

of chronic fatigue and somatization with depression [7]; suicidal attempts; and depression's association with neuroinflammatory and neurodegenerative disorders [8], general medical conditions especially immune- and O&NS-mediated disorders [8,9] and other psychiatric disorders [10]. As such immune-inflammatory and O&NS processes provide a conceptual framework in which to better incorporate the diverse range of data linked to depression.

The objectives of this article are: 1) to review the role that immune-inflammatory and O&NS pathways play in depression's etiology, course and treatment; and 2) to discuss the pharmacological treatment implications, including the use of combination treatments, whereby immune- and/or O&NS-targeted therapies may be utilized to enhance conventional antidepressants' efficacy.

2. Immune-inflammatory and O&NS pathways in depression's etiology and course.

There is now evidence that depression is accompanied by signs of activated immune-inflammatory and O&NS pathways, including signs of a low grade inflammatory response and cell mediated immune (CMI) activation, increased O&NS damage to lipids, proteins, DNA and mitochondria, and autoimmune responses directed against oxidatively or nitrosatively damaged epitopes. The available evidence is summarized in the following sections.

2.1. Immune activation

Increased levels of immune activation occur in depression, evidenced by increased interferon-gamma (IFN- γ) and neopterin [11] from associated T-helper (Th)-1 activation [12]. Th-1 immune activation increases interleukin (IL)-2 as well as IFN- γ , with IL-2 inducing immune cell proliferation, differentiation and activation [13]. As a consequence of such indicators of cell-mediated immunity (CMI), depression can be conceptualized as a CMI-mediated disorder, driven by increased O&NS [5]. Many CMI indicants occur in depression, including increased soluble IL-2R (sIL-2R), sCD8 [14,15], neopterin [5], and IL-12 [16] as well as decreased tryptophan [3,5]. While potentially confounded by variations in comorbid somatization and changes in the biological underpinnings during recurrent depression, increased CMI is a robust finding in depression [17]. The mechanisms driving the influence of systemic immune activation on central processes is partly mediated by indoleamine 2,3-dioxygenase (IDO) activation by CMI products, especially IFN- γ , but also IL-1, IL-6, IL-12, IL-18 and tumor necrosis factor-alpha (TNF- α) [18,19]. In inducing IDO, IFN- γ and other cytokines that are elevated in depression, including IL-1 and TNF- α , may drive tryptophan to the production of kynurenine (kyn) and subsequent tryptophan catabolites (TRYCATs), such as the neuroregulatory kynurenic acid (KYNA) and quinolinic acid and away from serotonin, N-acetylserotonin (NAS) and melatonin production. Decreased plasma tryptophan and increased kyn are robust findings in depression [20,21], especially in association with somatization [22]. Peripheral kyn is readily transported over the blood-brain barrier (BBB) where it is taken up by CNS cells especially astrocytes and microglia, which subsequently produce a

range of neuroregulatory TRYCATs, including quinolinic acid by microglia [23]. This allows factors acting on systemic immunity to impact on central processing.

Further CMI changes common in depression include increased Th-17 cells and IL-17 production. IL-6 levels are increased in depression [24], which in the presence of transforming growth factor-beta1 (TGF-1) promotes Th-17 cell differentiation and proliferation. The CMI driven increase in kyn and KYNA, via their activation of the aryl hydrocarbon receptor (Ahr) can also induce Th-17 differentiation [25]. Autoimmunity is highly associated with the relatively more prolonged and damaging effects of activated Th-17 cells, with autoimmunity in depression [26] thought to contribute to alterations in the biological underpinnings of recurrent depression, and thereby with the emergence of treatment resistance [3]. Together, these findings highlight the significant impacts of CMI products on the central changes driving depression, contributing to its progressive biological underpinnings over time.

2.2. Low grade inflammation

Further indicants of immune-inflammation are also evident in depression, both peripherally and centrally. In a post-mortem study of medication-free depressed patients, increased levels of the pro-inflammatory cytokines IL-2, IL-6, IL-12A, IL-18, IFN- and TNF- were found in the prefrontal cortex coupled to increased indicators of apoptotic processes [27,28]. Peripheral pro-inflammatory cytokines were also raised, with increases in IL-1 and its' counteracting IL-1 receptor antagonist (IL-1RA), generally

indicative of monocyte/macrophage activation in depression [12]. Single nucleotide polymorphisms (SNP) in immune-inflammatory genes, such as IL-1 [29], IL-6 [30], TNF- α [31], monocyte chemoattractant protein -1 [32] and T-cell regulatory function genes [33], modulate depression susceptibility and support the role of immune-inflammation in the etiology of depression. These genetic susceptibility SNPs code for a wide range of immune-inflammatory factors and further highlight the importance of CMI and inflammation in depression.

Pro-inflammatory cytokines in depression increase production of the positive acute phase proteins such as haptoglobin, ceruloplasmin and C-reactive protein, whilst decreasing production of the negative acute phase proteins such as albumin and transferrin [34,35]. Changes in acute phase proteins co-occur with other alterations to inflammatory responses, including changes in the complement system in depressed patients, where increases in C3C and/or C4 have been shown [35,36].

Further possible consequences of the low grade inflammatory status in depression are hypothalamic-pituitary-adrenal (HPA)-axis hyperactivity including glucocorticoid resistance and increased baseline activity of the HPA axis [37]. Indeed, pro-inflammatory cytokines, such as IL-1, may activate the HPA-axis and downregulate glucocorticoid receptors, thus elucidating the positive association between indicants of inflammation and HPA-axis hyperactivity in depression [37]. In contrast to acute stress, chronic and cortisol exposure increase monoamine oxidase (MAO) levels, in turn increasing the metabolism of monoamines, including serotonin [38]. Prolonged exposure to IL-1, TNF- α or IL-6 increases the uptake of serotonin by the serotonin

transporter [39]. This decreases serotonin availability, thereby decreasing melatonin and N-acetylserotonin production. Low grade inflammation also reduces the neurotrophins brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF) at both mRNA and protein levels [40].

2.3. Activated O&NS pathways

2.3.1. O&NS

Increased O&NS levels are evident in depressed individuals, contributing to raised levels of lipid peroxidation, protein carbonylation, DNA damage, telomere shortening and related O&NS damage [5,41]. Given that mitochondria are significant sources of reactive oxygen species (ROS), coupled to the brain's high metabolic rate, O&NS is particularly evident in the brain. Damage can be driven by relatively minor stressors such as examination stress, which increase the susceptibility to DNA damage and lipid peroxidation, and leads to reduced lymphocyte proliferation to mitogens and antigens [42,43]. Malondialdehyde, a lipid peroxidation marker, is increased in acute and recurrent depressed patients versus controls [44]. Increased 8-hydroxy-deoxyguanosine is found in depression, an indicator of DNA damage [45], in turn inducing the DNA repair response. The DNA repair response increases poly(ADP-ribose) polymerase (PARP), which decreases nicotinamide (NAD⁺), leading to suboptimal mitochondria functioning [46], which further contribute to mitochondrial ROS production. 4-hydroxynonenal (4-HNE) is another oxidant that is elevated in those with mood disorders [47] and is

produced via lipid peroxidation, as a result of the effects of peroxides and ROS on ω 6 polyunsaturated fatty acids (PUFAs) [48]. In depression, nitrosative stress is driven by protein nitrosylation, leading to nitric oxide (NO) adducts such as NO-tyrosine and NO-tryptophan [49,50]. The latter findings in depression indicate chronic hyperproduction of NO, damage to proteins by nitrosative stress and the genesis of autoimmune responses against the newly formed (neo)epitopes.

2.3.2. Decreased antioxidant levels

Coupled to increased O&NS levels in depression is a lowering of endogenous antioxidants, including alpha-tocopherol, independent of dietary intake [51], glutathione (GSH) [52], co-enzyme Q10 (CoQ10) [53], glutathione peroxidase (GPx) [54], zinc [55], melatonin [56], selenium [57], and total antioxidant capacity [58]. Decreased antioxidants levels contribute to O&NS damage in depression, as well as modulating many wider cellular processes and system functions, including immune system regulation [59]. Coupled to decreased endogenous antioxidants is a decreased ω 3/6 PUFA ratio in depressed patients [60], contributing to the pro-inflammatory environment and oxidant levels. There is a bidirectional relationship in this regard, with lower dietary ω 3 PUFA intake a risk factor for depression, with oxidative stress and secondary lipid peroxidation further depleting stores [61].

2.3.3. Mitochondrial pathways

Mitochondrial dysfunction is commonly found in depression [62] and correlates with depressive clinical presentations [63]. When mitochondrial deletions occur, they are often associated with severe depression [64]. Also in many other depression-associated conditions, particularly bipolar disorder, mitochondrial dysfunction is evident [3,8,65]. As well as being a major contributor to levels of cellular ROS, mitochondrial dysregulation decreases adenosine triphosphate (ATP), lowering cellular energy. The antioxidants compromised in depression, including alpha-tocopherol, GSH and superoxide dismutase, are crucial to mitochondrial functioning, contributing to depressive symptoms and association with neurodegenerative disorders [66]. Oxidant driven DNA damage, leading to increased PARP and decreased NAD⁺ and sirtuins will also modulate mitochondrial functioning. Sirtuins are a group of seven NAD⁺ induced histone deacetylases, of which sirtuin-1 and sirtuin-3 have been most extensively investigated, with sirtuin-1 alleles showing a genetic association with depression [67]. Some sirtuins show an association with increased longevity, in part via the inhibition of the pro-apoptotic factor, p53, but also by other means, including their regulation of mitochondria [68]. Sirtuin-1 is a significant regulator of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1), the master mitochondrial co-ordinator. 4HNE can change the configuration of sirtuin-3, decreasing mitochondria-located sirtuin-3 function [69]. With peroxides and ROS driving 4HNE production via ω 6 products, the decreased ω 3/6 PUFA ratio in depression contributes to mitochondrial dysregulation. As well as having antioxidant effects, zinc also regulates PUFA metabolism, thereby also modulating mitochondrial function [70]. As such O&NS drives mitochondrial

dysregulation, which in the absence of adequate antioxidants further contributes to O&NS and wider cellular and system dysregulation.

2.3.4. Secondary autoimmune responses to O&NS damage

O&NS driven membrane damage exposes the immune system to fragments not recognized as self. Such neoepitopes induction may generate IgM or IgG mediated autoimmune responses [49], including IgG autoantibodies against low density lipoprotein (LDL) and this is believed to contribute to depression association with atherosclerosis [71]. O&NS may also drive autoimmune responses to serotonin [72], further dysregulating serotonergic activity. The induction of autoimmunity is important in changing the biological underpinnings of long-standing and recurrent depression driving neuroprogression (See Section 2.5).

2.4. Gut Permeability and Inflammatory Disorders

Increased gut permeability and associated bacterial translocation may contribute to immune responses in depression [73]. Gut permeability, in driving immune-inflammation and O&NS, is proposed to contribute to cytokine-induced IDO and TRYCAT production, leading to increased kyn transfer over the BBB and thereby contributing to central changes driving depression [3]. Increased gut permeability may contribute to treatment resistance and chronicity in depression by contributing to immune activity and autoimmunity. There is considerable interest in the role of the microbiome, which has

many immune modulatory effects. Some identified gut commensals produce molecular hydrogen, which has in vitro and in vivo antioxidant properties, which might have treatment implications in mood disorders [74].

Many other medical conditions, including inflammatory bowel diseases, psoriasis and many cancers [75], as well as neurodegenerative and other psychiatric conditions [8] are associated with heightened levels of immune-inflammation and O&NS. All of these other medical conditions have high rates of concurrent depression, the biological underpinnings of which, in the case of central disorders, may be an integral part of degenerative processes [9].

2.5. Neuroprogression

As a consequence of the changes induced by O&NS and immune-inflammatory processes [76] recent conceptualizations of depression have emphasized its changing nature over time, a process termed neuroprogression [5,77]. Neuroprogression incorporates many related changes occurring over the course of recurrent depressive episodes, including neuronal apoptosis, decreased neurogenesis and increased autoimmune responses [78,79]. Immune-inflammatory and O&NS facilitated changes in mitochondrial functioning and membrane damage driven autoimmune responses, including to serotonin, are thought to drive depressive neuroprogression. These neuroprogressive processes lead to alterations in brain structure and cognition, and may be associated with reduced treatment response over time, although data are mixed

[80]. The changes occurring over the course of neuroprogression result in the understanding of depression to be more intimately aligned to the etiology and course of many neurodegenerative disorders [8].

3. Immune-inflammation and O&NS: antidepressant Interactions.

Reconceptualizing the biological underpinnings of depression provides new insights informing novel treatment approaches.

3.1. Immune-inflammation, O&NS and treatment resistant depression

Serum sIL-2R and IL-6 are generally increased in depression; especially when treatment resistance is evident [81]. Increased TNF- α , as well as an elevated CD4 $^{+}$ /CD8 $^{+}$ T cell ratio, is associated with treatment resistant depression [21]. BDNF genotypes also modulate the susceptibility to treatment resistance [82], suggesting that immune-inflammation induced decreases in BDNF contribute to treatment resistance. Decreased serum coenzyme Q10 and zinc [51,83,84] are associated with treatment resistance. The potent redox modulator melatonin regulates CoQ10 levels [85], suggesting that decreased serotonin availability for melatonin production, including in astrocytes, may also modulate treatment resistance [86].

Reciprocal relationships between the immune-inflammatory and O&NS pathways may confer risk of treatment resistance, given that peripheral TNF- α decreases pineal melatonin production [87] and melatonin can increase CoQ10 as well as afford wider mitochondria protection [85].

3.2. Immune-inflammation, O&NS and depression chronicity

Treatment resistance is intimately associated with chronicity and recurrent episodes. Increased gut permeability and autoimmune responses directed against multiple O&NS modified epitopes contribute to immune activation and thereby modulating depression chronicity. Some chronicity effects are driven via ageing associated processes, including decreases in longevity-associated sirtuins but also in telomere length [88]. Such impacts on ageing processes contribute to depression's association with neurodegenerative disorders. Given the induction of sirtuin-1 by melatonin and melatonin's wider antioxidant and anti-inflammatory effects coupled to increasing mitochondrial functioning and oxidative phosphorylation [89], it is of note that the melatonin receptor (MT2r) is a susceptibility gene for chronicity in depression [90]. Melatonin and the activation of its receptors are dependent on serotonin availability, including in astrocytes [86], suggesting that local central melatonin and its receptor activation may be decreased in depression.

3.3. Immune-inflammatory pathways and sensitization

CMI biomarkers such as neopterin, and cytokines such as TNF- α , correlate positively with the number of depressive episodes, suggesting that immune-inflammatory pathways contribute to sensitization in depression [91]. This is also supported by the increased serum sIL-1RA and IL-6 evident in women, postpartum, who had previously

experienced a depressive episode [92]. A consequence of increased levels of immune-inflammatory processes and O&NS is neuronal sensitization to other stimuli; such as IFN- mediated sensitization to the effects of the Alzheimer's disease-associated amyloid- β peptide [93]. Sensitization is another factor contributing to neuroprogression, ageing and neurodegenerative disorders. As to whether sensitization differentially occurs in some neurons, making it a process akin to competitive weakening or elimination requires investigation.

4. Immune-targeted therapies to enhance antidepressant efficacy.

Attempts to accelerate and potentiate the effects of antidepressants, including the adjunctive use of pindolol (a 5-HT_{1A} antagonist) with SSRIs, have demonstrated some success [94]. However, a conceptualization of depression as driven by O&NS and immune-inflammatory processes supports the targeting of these factors in efforts to improve depression management, including risk of recurrence, chronicity, treatment resistance and neuroprogression. In the treatment of immune-inflammatory processes by etanercept in psoriasis [95] and Crohn's disease [96], there is a concurrent significant decrease in depression levels, strengthening the role of immune-inflammation in depression. The comparative efficacy of agomelatine, a melatonin MT_{1&2r} agonist and serotonin 2C_r antagonist, versus a range of SSRIs and serotonin and noradrenaline reuptake inhibitors (SNRIs) [97] is likely to reflect melatonin's enhanced antioxidant, anti-inflammatory and immune regulatory benefits.

4.1. Useful Combination treatments

A number of immune and O&NS-regulatory treatments have been tried adjunctive to conventional antidepressants, including acetylsalicylic acid [98], which decreases multiple oxidant markers, and, in an open-label trial, decreases the time to effective antidepressant response [99]. N-acetylcysteine (NAC), a precursor of GSH [100], improves antidepressants' efficacy in depressed bipolar disorder participants [101], as well as anhedonia in rodent chronic unpredictable mild stress (CUMS), suggesting preventative efficacy [102]. Ebselen, a GPx mimetic, likewise prevents CUMS induced depression, whilst attenuating CUMS induced IL-1 and cyclooxygenase (COX)2, as well as preventing cortex apoptosis [103]. The effects of Ebselen include increasing dopamine and NE levels [104].

Generally fruit and vegetable intake is lower in people with depression [105,106], increasing depression risk, while a range of dietary anti-oxidants show antidepressant efficacy in animal models, including curcumin, tumeric, resveratrol, quercetin and green tea's epigallocatechin gallate (EGCG), reviewed in [3]. Augmentation of SSRIs with ω 3 fatty acids enhances prevention of depressive-like symptoms in rodents [107], whilst a meta-analysis of double-blind, placebo-controlled trials of the ω 3 eicosapentaenoic acid (EPA) found EPA to have antidepressant efficacy per se [108], partly via pro-inflammatory cytokines inhibition [109]. Zinc also heightens antidepressant efficacy, although only significantly in treatment resistant depression [110].

Preliminary data demonstrates minocycline, an anti-inflammatory tetracycline derivative shown to inhibit microglial activation, can also improve antidepressant efficacy [111], including sub-effective doses of desipramine [112]. Although the clinical utility of minocycline needs balancing against its side-effects, it does support the role O&NS and immune-inflammation in the course and treatment of depression. Likewise some evidence supports the anti-inflammatory COX2 inhibitors as antidepressants [113], although their long-term use may theoretically exacerbate depression, including by exacerbating Th1 driven responses, lipid peroxidation, neuroinflammation, bacterial gut translocation and neuroprogression, as well as decreasing key antioxidants [114]. Pioglitazone, an insulin-sensitizing agent with anti-inflammatory properties that includes the inhibition of the microglial inflammatory response [115], has efficacy in depression, a therapeutic effect not shared by metformin, a comparable insulin-sensitizing agent without clear effects on immunity [116]. Given the role of oxidants and controlled inflammatory processes in normal physiological functioning and given the role of autoimmune processes in depression, the dampening of O&NS and immune-inflammatory processes in depression may not necessarily find a straightforward solution in the administration of simple anti-inflammatories.

4.2. Multitargeting

Given the limitations imposed by the inhibition of single immune-inflammatory or O&NS factors on normal physiological functioning, it is likely that greater benefit might be attained from a multi-targeted dampening of the pathways and processes outlined. Such

multi-targeting is attained to some degree by factors such as NAC, acetylsalicylic acid, zinc, melatonin and ω 3. All these substances target multiple pathways, including O&NS, immune-inflammatory processes and mitochondrial functioning, and are potentially efficacious in augmenting prescribed antidepressants. Most conventional antidepressants have antioxidant, anti-inflammatory and negative immune regulatory effects [1,55,117]. It will be interesting to determine if specific adjunctive treatments, such as melatonin or NAC, have any particular useful interactions with specific antidepressants, as suggested for valproate with melatonin and vitamin D in multiple sclerosis treatment [118].

4.3. Other possible treatment targets

Targeting other pathways may also prove useful, including IL-1 [91,93]. Given that both IL-1 and IL-18 are increased in depression and modulate significant O&NS and immune-inflammatory pathways, their co-ordinated induction by the inflammasome requires investigation in depression [119]. With cellular plasticity associated O&NS and ceramide driving inflammasome induction [120] and IL-1 and IL-18 (formerly called IFN-inducing factor) being important inducers of IDO and the TRYCATs, the exploration of the inflammasome may be an important bridge between O&NS and immune-inflammation, and the investigation of its regulation in depression will be important to initiate. Increased IL-6 trans-signaling is another treatment target, given its induction of IDO [18] and its intimate association with autoimmune and epigenetic processes, including its inhibition by methyl-CpG-binding protein 2 (MeCP2) [121]. Melatonin

induces a trend increase in MeCP2 [122], which epigenetically silences IL-6 transcription [123], suggesting that, perhaps for subsets of patients with decreased local and/or pineal melatonin and raised IL-6, melatonin's regulation of MeCP2 may be of particular benefit, including via the inhibition of IL-6 induced IDO and TRYCATs. IL-6 interactions with MeCP2 and local melatonin at the glia-neuronal interface at sites of local inflammation [121] require testing. Targeting IDO is a feasible target, given the development of IDO inhibitors. However, activation of IDO and the TRYCAT pathway serves as a negative feedback CIRS (a compensatory anti-inflammatory reflex system) attenuating the primary immune response [5,21]. Thus, targeting IDO may theoretically dysregulate this beneficial CIRS response [21], while the wide immune dysregulation, including autoimmune responses, that occur in depression would not make this a practicable treatment choice. Targeting central TDO may prove useful, given the twenty-fold increase in central serotonin, increased neurogenesis and decreased anxiety in TDO knockout rodents [124], with central TDO suggested to significantly modulate human depression [21].

With increased gut permeability contributing to the immune-inflammation driven TRYCAT production that modulates central changes in depression, the targeting of gut permeability, including with dietary modification, zinc, NAC and glutamine [125] is another feasible treatment target readily screened at assessment. The microbiome too is emerging as an intriguing treatment opportunity [126]. Targeting secondary autoimmunity to neoepitopes may be another immune-linked screening target, with particular relevance to neuroprogression and chronicity prevention.

5. Conclusions

A conceptualization of depression that emphasizes the role of O&NS and immune-inflammatory processes in driving changes in neuroregulatory TRYCATs, neuroprogression and secondary autoimmune responses, in turn damaging serotonin, provides a more encompassing perspective on the nature of depression. This also provides treatment targets, whilst explaining the antidepressant efficacy of nutritional factors. Future benefits may accrue from a better understanding of the role of systemic immune-inflammatory pathways, including as activated by gut permeability, the microbiome and mechanisms underlying the central glia-neuronal interface at sites of inflammation. This will have wider benefits for depression associated conditions, especially the neuroinflammatory and neurodegenerative disorders.

Acknowledgements

Authors' contributions

GA and MM participated in the design of this review, while all authors helped to draft the paper. All authors contributed equally to this paper. All authors read and approved the final version.

Competing interests

No specific funding was obtained for this specific review.

MBk has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma and Servier, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Servier. OMD has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Cooperative Research Centre-Mental Health, Stanley Medical Research Institute, Lilly, NHMRC and an ASBD/Servier grant.

The other authors, GA, MM, OD and SM, declare that they have no competing interests.

References

1. Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. *Inflammopharmacol.* 2012;20(3):127-50.
2. Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. *Cochrane Database Syst Rev.* 2009;(3):CD007954.

3. Anderson G, Maes M. Oxidative/Nitrosative Stress and immune-inflammatory pathways in depression: treatment implications. *Curr Pharmacol Design*. In press.
4. Maes M, Bosmans E, Suy E, et al. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. *Neuropsychobiol*. 1990;24(3):115–20.
5. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. *Neurosci Biobehav Rev*. 2012;36(2):764-85.
6. Maes M, Galecki P, Chang YS, et al. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. *Prog. Neuropsychopharm Biol Psychiatry*. 2011;35(3):676–692.
7. Anderson G, Maes M, Berk M. Biological Underpinnings of the commonalities in depression, somatization, and chronic fatigue syndrome. *Med Hypotheses*. 2012;78:752-756.

8. Maes M, Kubera M, Obuchowiczwa E, et al. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. *Neuro Endocrinol Lett.* 2011;32(1):7-24.
9. Anderson G, Maes M. TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease. *CNS Neurol Dis-Drug Target.* In press.
10. Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased expression of depression through activation of immune-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. *Prog NeuroPsPharm Bio Psychiatr.* 2013;42:101-14.
11. Wachter H, Fuchs D, Hausen A, et al. Neopterin; biochemistry, methods, and clinical application. Berlin-New York: Walter de Gruyter; 1992.
12. Song C, Halbreich U, Han C, et al. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. *Pharmacopsychiatry.* 2009;42(5):182-8.

13. Caruso C, Candore G, Cigna D, et al. Biological significance of soluble IL-2 receptor. *Mediat Inflamm*. 1993;2(1):3-21.
14. Maes M, Vandoolaeghe E, Ranjan R, et al. Increased serum soluble CD8 or suppressor/cytotoxic antigen concentrations in depression: suppressive effects of glucocorticoids. *Biol Psychiatry*. 1996;40(12):1273-81.
15. Sluzewska A, Rybakowski J, Bosmans E, et al. Indicators of immune activation in major depression. *Psychiatry Res*. 1996;64(3):161-7.
16. Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. *Int Pharmacol*. 2006;6(8):1298-304.
17. Anderson G, Maes M, Berk M. Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. *Adv Protein Chem Struct Biol*. 2012;88:27-48.

18. Kim H, Chen L, Lim G, et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. *J Clin Invest*. 2012;122(8):2940-54.
19. Liebau C, Baltzer AW, Schmidt S, et al. Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. *Anticancer Res*. 2002;22(2A):931–936.
20. Maes M, Scharpé S, Meltzer HY, et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. *Psychiatry Res*. 1994;54(2):143–60.
21. Maes M, Leonard BE, Myint AM, et al. The new 5-HT hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35(3):702-21.
22. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. *Psychiatr Res*. 2012;196(23):243-9.

23. Saito K, Nowak TS Jr, Suyama K et al (1993) Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation. *J Neurochem* 61:2061–70.
24. Anderson G, Maes M. IL-6 and depression: Role of IDO, MeCP2 and local melatonin. *Pharmacol Reports*. In press.
25. Nguyen, N. T. et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. *Proc Natl Acad Sci USA*. 2010;107:19961–6.
26. Chen Y, Jiang T, Chen P, et al. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. *Psychiatry Res*. 2011;188(2):224-30.
27. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. *Mol Psychiatry*. 2011;16(7):751-62.

28. Dean B, Tawadros N, Scarr E, et al. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. *J Affect Disord.* 2010;120 (1–3):245–48.
29. Yu YW, Chen TJ, Hong CJ, et al. Association study of the interleukin-1 beta (C-511 T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. *Neuropsychopharmacol.* 2003;28:1182–5.
30. Bull SJ, Huezio-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. *Mol Psychiatry.* 2009;14:1095–104.
31. Jun TY, Pae CU, Hoon-Han, et al. Possible association between -G308A tumor necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. *Psychiatr Genet.* 2003;13:179–81.
32. Pae CU, Yu HS, Kim TS, et al. Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. *Psychiatry Res.* 2004;127:279–81.

33. Wong ML, Dong C, Maestre-Mesa J, et al. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. *Mol Psychiatry*. 2008;13:800–12.
34. Maes M. A review on the acute phase response in major depression. *Rev Neurosci*. 1993;4(4):407–416.
35. Song C, Dinan T, Leonard BE. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. *J Affect Disord*. 1994;30(4):283–8.
36. Berk, M, Wade AA, Kuschke RH, et al. Acute phase proteins in major depression. *J Psychosom Res*. 1997;43(5):529–34.
37. Maes M, Bosmans E, Meltzer HY, Scharpé S, Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? *Am J Psychiatry*. 1993;150(8):1189-93.

38. Soliman A, Udemgba C, Fan I, Xu X, Miler L, Rusjan P, Houle S, Wilson AA, Pruessner J, Ou XM, Meyer JH. Convergent effects of acute stress and glucocorticoid exposure upon MAO-A in humans. *J Neurosci*. 2012;32(48):17120-7.
39. Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. *Neuropsychopharmacol*. 2006;31(10):2121–31.
40. Song, C., Wang, H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35(3):760–8.
41. Phillips AC, Robertson T, Carroll D, et al. Do symptoms of depression predict telomere length? Evidence from the west of Scotland twenty-07 study. *Psychosom Med*. 2013;75(3):288-96
42. Sironova M, Zitnanova I, Hlincikova L, et al. Oxidative stress in university students during examinations. *Stress*. 2004;7(3):183–8.

43. Wadee AA, Kuschke RH, Kometz S, et al. Personality factors, stress and immunity. *Stress Health*. 2001;17(1):25-40
44. Stefanescu C, Ciobica A. The relevance of oxidative stress status in first episode and recurrent depression. *J Affect Disord*. 2012;143(1-3):34-8.
45. Maes M, Mihaylova I, Kubera M, et al. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis / chronic fatigue syndrome. *Neuro Endocrinol Lett*. 2009;30(6):715–22.
46. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD⁺ metabolism in human tissue. *PLoS One*. 2012;7(7):e42357.
47. Wang JF, Shao L, Sun X, Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. *Bipolar Disord*. 2009;11(5):523-9.

48. N. Zarkovic. 4-Hydroxynonenal as a bioactive marker of pathophysiological processes. *Mol Asp Med*. 2003;24(4-5):281–91.
49. Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. *J Affect Disord*. 2011;135(1-3):414-8.
50. Ohmori H, Kanayama N. Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins. *Autoimmun Rev*. 2005;4(4):224–9.
51. Owen AJ, Batterham MJ, Probst YC, et al. Low plasma vitamin E levels in major depression: diet or disease? *Eur J Clin Nutr*. 2005;59(2):304–6.
52. Kodydková J, Vávrová L, Zeman M, et al. Antioxidative enzymes and increased oxidative stress in depressive women. *Clin Biochem*. 2009;42(13–14):1368–74.

53. Maes M, Mihaylova I, Kubera M, et al. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. *Neuro Endocrinol Lett.* 2009;30(4):462-9.
54. Maes M, Mihaylova I, Kubera M, et al. Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: lower GPX activity as another pathway explaining the increased incidence of coronary artery disease in depression *Neuro Endocrinol Lett.* 2011;32(2):133-40.
55. Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. *Redox Rep.* 2003;8(6):365–70.
56. Khaleghipour S, Masjedi M, Ahade H, et al, Morning and nocturnal serum melatonin rhythm levels in patients with major depressive disorder: an analytical cross-sectional study. *Sao Paulo Med J.* 2012;130(3):167-72.
57. Pasco JA, Jacka FN, Williams LJ, et al. Dietary selenium and major depression: a nested case-control study. *Complement Ther Med.* 2012;20(3):119-23.

58. Cumurcu BE, Ozyurt H, Etikan I, et al. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. *Psychiatry Clin Neurosci*. 2009;63(5):639–45.
59. Kim HJ, Barajas B, Wang M, et al. Nrf2 activation by sulforaphane restores the age-related decrease of T(H)1 immunity: role of dendritic cells. *J Allergy Clin Immunol*. 2008;121(5):1255-61.
60. Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. *Psychiatry Res*. 1999;85(3):275–91.
61. Jacka FN, Pasco JA, Henry MJ, et al. Dietary omega-3 fatty acids and depression in a community sample. *Nutr Neurosci*. 2004;7(2):101-6.
62. Shao L, Martin MV, Watson SJ, et al. Mitochondrial involvement in psychiatric disorders. *Ann Med*. 2008;40(4):281–95.

63. Gardner A, Johansson A, Wibom R, et al. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. *J Affect Disord*. 2003;76(1–3):55–68.
64. Suomalainen A, Majander A, Haltia M, et al. Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia. *J Clin Invest* 1992;90(1):61–6.
65. Nierenberg AA, Kansky C, Brennan BP, et al. Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. *Aust N Z J Psychiatry*. 2013;47(1):26-42.
66. Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. *Trends Pharmacol Sci*. 2008;29(7):346-51.
67. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Fukuo Y, Naitoh H, Umene-Nakano W, Inada T, Nakamura J, Ozaki N, Iwata N. SIRT1 gene is associated with major depressive disorder in the Japanese population. *J Affect Dis*. 2010;126:167–73.

68. Verdin E, Hirschey MD, Finley LWS, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. *Tr Biochem Sci*. 2010;35(12):669-75.
69. Fritz KS, Galligan JJ, Smathers RL, et al. 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. *Chem Res Toxicol*. 2011;24(5):651-62.
70. Szewczyk B, Kubera M, Nowak G. The role of zinc in neurodegenerative and inflammatory pathways in depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35(3):693–701.
71. Maes M, Mihaylova I, Kubera M, et al. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. *J Affect Disord*. 2010;125(1-3):287-94.
72. Maes M, Ringel K, Kubera M, et al. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. *J Affect Disord*. 2012;136(3):386-92.

73. Maes M, Kubera M, Leunis JC, et al. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. *Acta Psychiatr Scand*. 2013; In press.

74. Ghanizadeh A, Berk M. Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. *Med Gas Res*. 2013;3(1):11.

75. Anderson G, Beischlag TV, Vinciguerra M, Mazzocchi G. The circadian clock circuitry and the AHR signaling pathway in physiology and pathology. *Biochem Pharmacol*. 2013;85:1405–16

76. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. *Neuro Endocrinol Lett*. 2008;29(3):287–91.

77. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. *Int J Neuropsychopharmacol*. 2009;12(4):441–5.

78. Moylan S, Maes M, Wray NR, et al. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. *Mol Psychiatry*. 2013;18(5):595-606.
79. Maes M, Kubera M, Mihaylova I, et al. Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: Implications for the pathways to chronic depression and neuroprogression. *J Affect Disord*. In press.
80. Dodd S, Berk M, Kelin K, et al. Treatment response for acute depression is not associated with number of previous episodes: Lack of evidence for a clinical staging model for major depressive disorder. *J Affect Disord*. In press.
81. Maes M, Bosmans E, De Jongh R, et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. *Cytokine*. 1997;9(11):853-8.
82. Anttila S, Huuhka K, Huuhka M, et al. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. *J Neural Transm*. 2007;114(8):1065–8.

83. Morris G, Anderson G, Berk M, et al. Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. *Mol Neurobiol*. In press.
84. Maes M, Vandoolaeghe E, Neels H, et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. *Biol Psychiatry*. 1997;42(5):349–58.
85. Yalcin A, Kilinc E, Kocturk S, et al. Effect of melatonin cotreatment against kainic acid on coenzyme Q10, lipid peroxidation and Trx mRNA in rat hippocampus. *Int J Neurosci*. 2004;114(9):1085-97.
86. Liu YJ, Meng FT, Wang LL, Zhang LF, Cheng XP, Zhou JN. Apolipoprotein E influences melatonin biosynthesis by regulating NAT and MAOA expression in C6 cells. *J Pineal Res*. 2012;52(4):397-402.
87. Pontes GN, Cardoso, EC, Carneiro-Sampaio MM, et al. Pineal melatonin and the innate immune response: the TNF- α increase after cesarean section suppress nocturnal melatonin production. *J Pineal Res*. 2007;43:365–71.

88. Wolkowitz OM, Mellon SH, Epel ES, et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings. *PLoS One*. 2011;6(3):e17837.
89. Martín M, Macías M, León J, et al. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. *Int J Biochem Cell Biol*. 2002;34(4):348-57.
90. Galecka E, Szemraj J, Florkowski A, et al. Single nucleotide polymorphisms and mRNA expression for melatonin MT(2) receptor in depression. *Psychiatry Res*. 2011;189(3):472-4.
91. Maes M, Mihaylova I, Kubera M, et al. Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012;36(1):169-75.
92. Maes M, Ombelet W, De Jongh R, Kenis G, Bosmans E. The inflammatory response following delivery is amplified in women who previously suffered from major

depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. *J Affect Disord.* 2001;63(1-3):85-92.

93. Bate C, Kempster S, Last V, et al. Interferon-gamma increases neuronal death in response to amyloid-beta 1-42. *J Neuroinflamm.* 2006;3:7.

94. Portella MJ, de Diego-Adeliño J, Ballesteros J, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. *J Clin Psychiatry.* 2011;72(7):962-9.

95. Tying S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, and Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. *Lancet.* 2006;367:29-35.

96. Lichtenstein GR, Bala M, Han C, DeWoody K, and Schaible T. Infliximab improves quality of life in patients with Crohn's disease. *Inflammatory Bowel Disease* 2002;8:237-43.

97. Kasper S, Corruble E, Hale A, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. *Int Clin Psychopharmacol*. 2013;28(1):12-9.
98. Gałecki P, Szemraj J, Bienkiewicz M, et al. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. *Hum Psychopharmacol*. 2009;24:277–86.
99. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. *Int Clin Psychopharmacol*. 2006;21(4):227-31.
100. Samuni Y, Goldstein S, Dean OM, et al. The chemistry and biological activities of N-acetylcysteine. *Biochim Biophys Acta*. 2013;1830(8):4117-29.
101. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. *Biol Psychiatry*. 2008;64(6):468–75.

102. Arent CO, Réus GZ, Abelaira HM, et al. Synergist effects of n-acetylcysteine and deferoxamine treatment on behavioral and oxidative parameters induced by chronic mild stress in rats. *Neurochem Int.* 2012;61(7):1072-80.
103. Lee YJ, Choi B, Lee EH, et al. Immobilization stress induces cell death through production of reactive oxygen species in the mouse cerebral cortex. *Neurosci Lett.* 2006;392(1–2):27–31.
104. Posser T, Kaster MP, Baraúna SC, et al. Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system. *Eur J Pharmacol.* 2009;602(1):85–91.
105. McMartin SE, Jacka FN, Colman I. The association between fruit and vegetable consumption and mental health disorders: evidence from five waves of a national survey of Canadians. *Prev Med.* 2013;56(3-4):225-30.
106. Payne ME, Steck SE, George RR, et al. Fruit, vegetable, and antioxidant intakes are lower in older adults with depression. *J Acad Nutr Diet.* 2012;112(12):2022-7.

107. Lakhwani L, Tongia SK, Pal VS, et al. Omega-3 fatty acids have antidepressant activity in forced swimming test in Wistar rats. *Acta PolPharm.* 2007;64(3):271–6.
108. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. *J Clin Psychiatry.* 2007;68(7):1056–61.
109. Song C, Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. *Prog Neuropsychopharmacol Biol Psychiatry.* 2011;35(3):760–8.
110. Siwek M, Dudek D, Paul IA, et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. *J Affect Disord.* 2009;118(1–3):187–95.
111. Pae CU, Marks DM, Han C, et al. Does minocycline have antidepressant effect? *Biomed Pharmacother.* 2008;62(5):308–11.

112. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32(2):380–6.
113. Müller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. *Mol Psychiatry*. 2006;11:680–4.
114. Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. *Metab Brain Dis*. 2012;27(4):405-13.
115. Ji H, Wang H, Zhang F, Li X, Xiang L, Aiguo S. PPAR γ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. *Inflamm Res*. 2010;59(11):921-9.
116. Kashani L, Omidvar T, Farazmand B, et al. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. *Psychoneuroendocrinol*. 2013;38(6):767-76.

117. Bilici M, Efe H, Köroğlu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. *J Affect Disord.* 2001;64(1):43–51.
118. Anderson G, Rodriguez M. Multiple Sclerosis, seizures and anti-epileptics: role of IL-18, IDO and melatonin. *Eur J Neurol.* 2011;18(5):680-5.
119. Iwata M, Ota KT, Duman RS. The inflammasome: Pathway linking psychological stress, depression, and systemic illnesses. *Brain Behav Immun.* In press.
120. Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. *J Neurosci Res.* 2010;88(8):1615–31
121. Anderson G, Maes M. IL-6 and Depression: Role of IDO, MeCP2 and local melatonin. *Pharm Rep.* In press.

122. Sharma R, Ottenhof T, Rzeczkowska PA, et al. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. *J Pineal Res.* 2008;45(3):277-84.
123. Dandrea M, Donadelli M, Costanzo C, et al. MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines. *Nucleic Acids Res.* 2009;37(20):6681-90.
124. Funakoshi H, Kanai M, Nakamura T. Modulation of tryptophan metabolism, promotion of neurogenesis and alteration of anxiety-related behavior in tryptophan 2,3-dioxygenase-deficient mice. *Int J Tryptophan Res.* 2011;4:7–18.
125. Wischmeyer PE. Glutamine: role in gut protection in critical illness. *Curr. Opin Clin Nutr Metab Care.* 2006;9(5):607–12.
126. Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. *Trends Neurosci.* 2013;36(5):305-12.